In June 2010, Oscient Pharmaceuticals Corp went out of business as per its Chapter 11 liquidation filing under bankruptcy in July 2009. Oscient Pharmaceuticals Corporation (formerly Genome Therapeutics Corporation and originally did business as Collaborative Research) - a firm founded by Orrie Friedman, a major SBIR Pioneer. The firm ihad been a genomics-based drug target discovery company focusing on the discovery and characterization of novel targets in pathogens that are responsible for many serious diseases and human diseases. Active in genomics, the science of locating and characterizing disease genes, for a decade, while know as Genome Therapeutics, the fim had been using and improving its strength in multiplex, high-throughput sequencing primaril to identify likely targets for drug design, focusing initially on M. tuberculosis and H. pylori, and other major bacterial pathogens. The Company also worked on human genes involved in disease, including cancer and central nervous system disorders such as manic depression and schizophrenia.
